Product image of Ilgaper (Repaglinide) supplied by GNH India

Ilgaper

Active Ingredient:
Repaglinide
Origin:
EU

Ilgaper (Repaglinide)

Repaglinide, the active ingredient in Ilgaper, is a Meglitinide presented as a tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise. The drug acts by stimulating rapid insulin release from pancreatic beta‑cells, providing a short‑acting glucose‑lowering effect that is especially useful for post‑prandial glucose excursions.

GNH India supplies Ilgaper as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide across the globe.

Manufacturer / TM Owner

Sigillata Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Repaglinide is indicated for the management of type 2 diabetes mellitus, targeting post‑prandial hyperglycemia.

  • Type 2 diabetes mellitus: improves overall glycemic control when combined with diet and exercise.
  • Post‑prandial hyperglycemia: reduces glucose spikes after meals.
  • Adjunct therapy: used when other oral agents do not achieve target HbA1c.

How It Works

  • Repaglinide binds to the sulfonylurea receptor subunit of the pancreatic beta‑cell K‑ATP channel, causing channel closure, cell depolarization, calcium influx and rapid insulin secretion. This short‑acting stimulation lowers post‑prandial blood glucose levels without prolonged insulin release.

Side Effects

Repaglinide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Hypoglycemia: low blood sugar episodes, especially if meals are missed.
  • Nausea: mild stomach upset.
  • Headache: transient cranial discomfort.
  • Dizziness: light‑headed feeling.
  • Diarrhea: loose stools.
  • Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects

  • Severe hypoglycemia: prolonged low glucose requiring assistance.
  • Allergic reactions: rash, itching, or swelling.
  • Hepatotoxicity: abnormal liver enzyme elevations.
  • Pancreatitis: abdominal pain with elevated enzymes.

Precautions & Warnings

When prescribing Repaglinide, clinicians should consider several precautionary measures to ensure safe use.

  • Monitor blood glucose: adjust dose based on fasting and post‑prandial readings.
  • Renal impairment: use lower doses or avoid in severe dysfunction.
  • Hepatic impairment: consider dose reduction in moderate liver disease.
  • Concomitant sulfonylureas: avoid combined use to reduce hypoglycemia risk.
  • Elderly patients: start with the lowest effective dose and monitor closely.
  • Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Avoid Interactions

Repaglinide interacts with several medicines that can alter its glucose‑lowering effect or increase toxicity.

Major Interactions (Avoid)

  • Strong CYP2C8 inhibitors (e.g., gemfibrozil): may cause dangerous hypoglycemia.
  • Insulin or other sulfonylureas: additive risk of severe hypoglycemia.
  • MAO‑B inhibitors (e.g., selegiline): can enhance hypoglycemic effect.

Moderate Interactions (Monitor Closely)

  • CYP2C8 inducers (e.g., rifampicin): may reduce Repaglinide efficacy.
  • Beta‑blockers: may mask hypoglycemia symptoms.
  • NSAIDs (e.g., ibuprofen): can potentiate hypoglycemia in some patients.

Frequently Asked Questions

Ilgaper contains repaglinide, an oral hypoglycemic indicated for the management of type 2 diabetes mellitus in adults. It helps improve overall glycemic control, particularly post‑prandial glucose levels, when used together with diet and exercise.

Repaglinide binds to the sulfonylurea receptor subunit of the pancreatic beta‑cell K‑ATP channel, closing the channel, depolarizing the cell, and allowing calcium influx. This triggers a rapid release of insulin, providing a short‑acting reduction in blood glucose after meals.

The dose of repaglinide is individualized. A qualified prescriber determines the appropriate strength and dosing schedule based on the patient’s blood‑glucose profile, renal function, and any concomitant therapies. No fixed regimen is provided here.

Safety of repaglinide during pregnancy or lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

To request Ilgaper, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to repaglinide is the sulfonylurea class (e.g., glimepiride). Both stimulate insulin release, but repaglinide has a shorter onset and duration, offering more flexibility around meals and a lower risk of prolonged hypoglycemia compared with many sulfonylureas.

Ilgaper tablets should be stored at ambient temperature, below 25 °C, in the original blister or bottle, protected from moisture, heat and direct sunlight. Keep out of reach of children and do not use after the expiry date.

Ilgaper is taken orally, usually 15–20 minutes before meals. The exact timing and number of tablets per day are determined by the prescribing clinician based on the patient’s meal pattern and glucose monitoring results.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and rare allergic reactions such as rash, swelling or anaphylaxis. Prompt medical attention is required if these events occur.

Ilgaper is contraindicated in patients with known hypersensitivity to repaglinide or other meglitinides, in individuals with severe hepatic impairment, and in those taking other insulin‑secretagogues that could precipitate dangerous hypoglycemia. Caution is also advised in the elderly and in patients with renal dysfunction.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Repaglinide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT